Inmune Bio, Inc. has announced a strategic partnership with Uniphar Durbin Ireland Limited to facilitate the international commercialization of its allogeneic stromal cell therapy, Ebstrocel™. This agreement is a significant development for the company as it moves closer to making this innovative treatment available to patients suffering from Recessive Dystrophic Epidermolysis Bullosa (RDEB).
The partnership aims to establish a scalable framework for international access, distribution, and commercialization of Ebstrocel™, with an initial focus on named-patient access in selected European countries and the Middle East and North Africa (MENA) region. This approach allows physicians to request Ebstrocel™ for individual patients before broader marketing approval is granted, thus expediting access to the therapy.
Inmune Bio, a late-stage biotechnology company, is focused on developing treatments that target the innate immune system. The company’s innovative approach is particularly relevant in the biological products sector, where therapies are increasingly tailored to individual patient biology.
Background
Inmune Bio, Inc. is incorporated in Nevada and trades under the ticker symbol INMB on the Nasdaq. The company specializes in biological products, specifically those that do not include diagnostic substances, as classified under SIC 2836. Recently, Inmune Bio has made several filings, including an 8-K on October 21, 2026, detailing the new partnership and its implications for the company.
What the Filing Says
The recent filing states, "INmune Bio Inc. has prepared a slide deck that the Company intends to use in presentations from time to time. The Presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K." The filing also notes the issuance of two press releases regarding Ebstrocel™, highlighting the Master Services Agreement with Uniphar and the submission of a pre-Marketing Authorisation Application (pre-MAA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Impact
This partnership may significantly affect patients needing Ebstrocel™ by providing earlier access to the therapy. It also positions Inmune Bio to leverage Uniphar's established infrastructure, which includes regulatory feasibility assessments, market access, and distribution services. This capital-efficient model allows Inmune Bio to expand its international footprint without the need for extensive internal development.
What's Next
Following this agreement, Inmune Bio will focus on implementing named-patient access in the targeted regions while preparing for broader commercialization as regulatory approvals are secured. The filing does not specify what happens next beyond these immediate actions.